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Amadori-glycated albumin in diabetic nephropathy: Patho- failure. Additional work has shown that factors in the
physiologic connections. Nonenzymatic glycation of proteins diabetic milieu other than hyperglycemia are equally
represents a major mechanism by which hyperglycemia leads damaging. Prominent among these are circulating non-to diabetic renal disease. Recent research has shown that Ama-
enzymatically glycated proteins.dori-modified albumin, the principal glycated protein in plasma,
Glycated proteins arise from a condensation reaction,elicits pathobiologic effects in cultured renal cells that are iden-
tical to those of high ambient glucose. When added to the incuba- driven by the ambient glucose concentration, in which
tion media of glomerular mesangial and endothelial cells, gly- a free sugar covalently attaches to a protein at reactive
cated albumin stimulates protein kinase C (PKC) activity,
–NH2 groups. Glycation proceeds through the formationincreases transforming growth factor-b (TGF-b) bioactivity,
of a labile Schiff base adduct, which then undergoes anand induces gene overexpression and enhanced production of
extracellular matrix proteins. These cellular events, whereby intramolecular Amadori rearrangement to become a sta-
PKC-mediated TGF-b activation leads to increased matrix ex- ble glucose-modified protein. The reaction occurs slowly,
pression, are inextricably linked, and they form the central and the degree and duration of hyperglycemia influencetenets of a pathophysiologic connection between glycated pro-
the amount of glycated protein. Amadori-modified pro-teins and diabetic nephropathy. In vivo studies further corrobo-
teins may further evolve through a series of spontaneousrate the role of glycated proteins in the pathogenesis of diabetic
nephropathy. Reduction or neutralization of glycated albumin rearrangement, dehydration, and polymerization reac-
in the db/db mouse model of type 2 diabetes significantly ame- tions to become advanced glycation end products (AGEs).
liorates the proteinuria, renal insufficiency, mesangial expan-
The accelerated formation of glycated proteins in diabe-sion, and overexpression of matrix proteins. In human type 1
tes has prompted research into their role in the pathogen-diabetes, the plasma-glycated albumin concentration is inde-
pendently associated with the presence of nephropathy. Abro- esis of diabetic complications. Recent work has defined
gating the biologic effects of increased glycated albumin has Amadori products, which comprise the overwhelming
novel therapeutic potential in the management of renal compli- majority of glucose-modified proteins in plasma, as sub-cations in diabetes.
stantive contributors to the development of diabetic ne-
phropathy.
Large-scale clinical studies have established that hy-
perglycemia, the defining metabolic abnormality in dia- EFFECTS OF GLYCATED PROTEINS IN
betes mellitus, increases the risk for diabetic renal dis- THE KIDNEY
ease [1, 2]. Although these studies did not define the Earlier work demonstrated that glycated proteins in-
responsible mechanisms, research in the past decade has fluence renal function and have distinct renal handling.
shown that hyperglycemia has deleterious effects on kid- Infusion of Amadori-modified plasma proteins into nor-
ney cell function. Renal cell lines grown in high glucose mal rats induces glomerular hyperfiltration [6], an early
media exhibit activation of intracellular signaling path-
functional feature of diabetes, and repeated injections of
ways [3], up-regulation of the transforming growth fac-
glycosylated proteins into normal mice produce “pseudo-
tor-b (TGF-b) system [4], and a consequent overproduc-
diabetic” renal glomerular changes [7]. Glycated proteinstion of extracellular matrix molecules [5] that leads to
alter the permeability properties of the glomerular capil-glomerulosclerosis, tubulointerstitial fibrosis, and renal
lary wall [8] and are preferentially transported across
the glomerular filtration barrier and into the mesangial
space [9]. They appear in the urinary space in greaterKey words: nonenzymatic glycation, hyperglycemia, glomerulopathy,
protein kinase C, transforming growth factor-b. amounts as evidenced by their increased clearance rates
from the bloodstream, but final glycated protein concen-Ó 2000 by the International Society of Nephrology
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trations in urine actually decrease relative to those of of a PKC-specific substrate, and in the PKC-b1 isoform
activity, measured by the degree of cytosol-to-membranenonglycated proteins as patients with diabetes progress
from normoalbuminuria to frank proteinuria [10]. This translocation of this isoform [20]. We have performed
experiments of similar design with rat glomerular endo-suggests preferential tubule cell uptake of the glycated
forms of protein, which may have adverse consequences thelial cells and shown that glycated albumin also stimu-
lates PKC activity in this cell type independently of highin the tubulointerstitial compartment and in the renal
microvasculature. Endothelial cells preferentially take glucose concentrations [21].
up circulating glycated proteins, which may lead to endo-
Glycated proteins activate the TGF-b systemthelial dysfunction and contribute to diabetic microangi-
opathy [11]. TGF-b, a hypertrophic and prosclerotic cytokine, plays
a pivotal role in mediating the morphologic changes
Glycated protein receptors characteristic of diabetic nephropathy [22]. The biologic
effects of TGF-b in kidney cells, which include cell hyper-Putative mesangial and endothelial cell receptors rec-
ognize the Amadori-glycated form of albumin [12]. Li- trophy and stimulation of extracellular matrix produc-
tion, closely resemble those of hyperglycemia [23]. Wegand binding studies conducted on phenotypically stable,
nontransformed mesangial cells have demonstrated se- have reported that proximal tubule epithelial cells, mes-
angial cells, and renal interstitial cells and fibroblastslective binding of glycated albumin in a dose-dependent
and saturable manner and are consistent with the exis- cultured in high ambient glucose express significantly
increased TGF-b1 mRNA levels and bioactivity [24–27].tence of more than one affinity class of glycated albumin
receptors [12]. In competition experiments, a mono- The TGF-b system in turn stimulates collagen synthesis
in these cells [4, 27]. To examine whether glycated albu-clonal antiglycated albumin antibody specifically inhibits
binding of glycated albumin to the mesangial cell recep- min, independent of high ambient glucose, modulates
the TGF-b system in renal cells, we exposed culturedtor, without interfering with binding of nonglycated albu-
min to mesangial cells [12]. Although further work needs mouse mesangial cells to normal glucose media containing
glycated albumin at concentrations found in clinical spec-to be done to characterize the receptors for glycated
albumin, it is reasonable to surmise that activation of imens [28]. Northern blot analysis revealed that glycated
albumin significantly stimulated TGF-b1 mRNA levelsthis receptor by ligand binding may transduce important
downstream pathobiologic effects. by approximately twofold compared with nonglycated
albumin. It also induced a concomitant twofold increase
Glycated albumin increases protein kinase C activity in the mRNA expression of the type II TGF-b receptor,
the primary signaling receptor for TGF-b. ExtrapolatedSeveral studies have shown that the protein kinase C
(PKC) system is up-regulated in the diabetic state. PKC to the in vivo situation, these results suggest that glycated
albumin, which has a circulating half-life of about 2activity, measured by the cytosol-to-membrane shift of
various classical PKC isoforms, is increased in mesangial weeks, may continue to influence the TGF-b system long
after restoration of normoglycemia. Further, glycatedand endothelial cells incubated in high glucose media
[13–16]. Glomeruli from diabetic rodents also display albumin was nearly as potent as high glucose in stimulat-
ing expression of both TGF-b1 and its receptor. Addi-elevated PKC activity and cytosol-to-membrane translo-
cation of diacylglycerol-sensitive PKC isoforms [17, 18]. tionally, glycated albumin in high glucose media caused
an even greater increase in the TGF-b1 and type II TGF-bBased on a series of 14C-radiolabeling experiments, the
relationship between hyperglycemia and PKC activation receptor mRNAs [28]. Thus by stimulating the TGF-b
system at both the ligand and receptor levels, glycatedhas been ascribed to an increased intracellular metabo-
lism of glucose that promotes de novo formation of diacyl- albumin can amplify the pathobiologic effects of TGF-b
and can conspire with hyperglycemia to sustain theseglycerol, the major endogenous activator of PKC [19].
Our work has suggested additional mechanisms. Nota- effects.
bly, Amadori-glycated albumin, independent of glucose,
Glycated proteins stimulate extracellularcan trigger PKC activation in glomerular cells [20].
matrix synthesisWe assayed PKC activity in two renal cell types after
incubation with concentrations of glycated albumin that Mesangial expansion due to overproduction of extra-
cellular matrix proteins causes gradual obliteration ofare found in diabetic subjects. Cells incubated with equal
concentrations of nonglycated albumin served as the glomerular capillary lumens and a progressive decline
in effective filtration surface area [29]. Given the centralcontrols, and experiments were performed in normal
glucose media to avoid the confounding effects of high importance of the mesangium in diabetic nephropathy,
we first examined the responses of mesangial cells toglucose on the PKC system. Both rat and mouse mesan-
gial cells exhibited significant increases in the overall glycated proteins [30]. The primary endpoint in these
studies was expression of type IV collagen, the predomi-PKC activity, measured by the extent of phosphorylation
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nant constituent of the expanded mesangial matrix in in mesangial cells, generalized PKC inhibition by GF
109203X prevents the increased type IV collagen produc-diabetes. Mouse mesangial cells incubated for 72 h in
tion [21].media containing glycated serum proteins and a normal
The TGF-b system also mediates the glycated protein-glucose concentration displayed increased a1(IV) colla-
induced increases in extracellular matrix production [28].gen mRNA, an effect that was exaggerated in high glu-
The increase in fibronectin expression by mesangial cellscose media [31]. Inclusion of a monoclonal antibody
incubated with glycated serum or glycated albumin is(A717), site-specific for Amadori glucose adducts in gly-
prevented when the cells are concurrently treated withcated albumin, prevented the increase in type IV colla-
a neutralizing anti-TGF-b antibody [28]. Similarly, thegen production, indicating that glycated albumin was
elevation in type IV collagen production by glomerularprimarily responsible for the observed effect due to gly-
endothelial cells incubated with glycated albumin is at-cated serum proteins. Subsequent experiments established
tenuated in the presence of neutralizing anti-TGF-b anti-that glycated serum and glycated albumin significantly
bodies [21]. Further, inhibition of PKC with GF 109203Xincreased the expression of another matrix protein, fi-
prevents stimulation of both TGF-b and type IV collagenbronectin, and that this effect was also accentuated in
proteins, suggesting that PKC may indirectly signal in-high glucose media [28].
creased extracellular matrix production by stimulatingIn keeping with the paradigm that glycated albumin
the TGF-b system [36]. The presence of several PKC-contributes substantially to structural and functional ab-
responsive activated protein (AP-1) binding sites on thenormalities associated with diabetic renal disease, we
promoter of the TGF-b1 gene supports this hypothesismore recently studied the effects of this glycated protein
[37, 38].on the production of matrix by glomerular endothelial
cells [21, 32]. Compared with nonglycated albumin, gly- Glycated proteins in animal models of
cated albumin significantly increased the expression of diabetic nephropathy
fibronectin and type IV collagen, effects that were pre-
Animal studies have confirmed that the in vitro effectsvented by the A717 antiglycated albumin monoclonal
of glycated proteins are relevant in vivo, and that theyantibody. Thus, the glomerular endothelium, strategi-
play an important role in the pathophysiology of diabeticcally positioned between the circulation and the other
renal disease. The db/db mouse represents an animalglomerular elements, responds to an elevated glycated
model of type 2 diabetes that develops glomerulopathyprotein concentration in ways that promote glomerular
closely resembling that found in the human diseasepathology.
[39, 40]. As in humans, glycated albumin levels are two- to
Glomerular epithelial cells also respond to glycated threefold higher in diabetics than in nondiabetic controls.
proteins with increased extracellular matrix synthesis. Chronic administration of Fab fragments of the mono-
Cells exposed to glycated fetal bovine serum (FBS) com- specific antiglycated albumin antibody, A717, signifi-
pared with those exposed to nonglycated FBS show in- cantly lowers the plasma glycated albumin concentration
creased laminin protein and basement membrane matrix, in the db/db mouse [41]. After 8 weeks of treatment, the
but unchanged type I collagen and fibronectin proteins A717-treated db/db mice had significantly less urinary
[33]. Glycated FBS also decreases collagenase activity, albumin excretion than the db/db mice treated with irrel-
suggesting that in glomerular epithelial cells, glycated evant IgG, nearly achieving the normoalbuminuric state
proteins promote extracellular matrix accumulation in of the nondiabetic db/m controls [41]. The antibody
part through inhibition of matrix degradation. treatment protocol also remarkably improved glomeru-
lar pathology. Glomeruli from IgG-treated db/db con-Mediators of glycated protein-induced
trols showed diffuse mesangial expansion that encroachedextracellular matrix
on the normal capillary network, whereas the glomeruli
Activation of the PKC signaling pathway by glycated from A717-treated db/db mice showed considerably less
proteins has been causally linked to increased extracellu- mesangial expansion. Northern blot analysis revealed
lar matrix expression [20]. Incubation with glycated albu- that the gene expression of both a1(IV) collagen and
min activates PKC in cultured rat and mouse mesangial fibronectin were significantly increased in db/db mice com-
cells, and when overall PKC activity is blocked by GF pared with that in db/m mice [41]. Additional experi-
109203X, the glycated albumin-evoked increase in type ments demonstrated that the lowering of plasma glycated
IV collagen production is prevented. Likewise, when albumin in db/db mice by A717 delayed the development
PKC-b activity is specifically blocked by LY-379196, the of renal insufficiency, assessed by the level of azotemia
increase in type IV collagen synthesis is prevented to and the creatinine clearance [42].
the same degree, consistent with the notion that the b
Glycated proteins in human diabetic nephropathyisoform plays a predominant role among the PKC iso-
types [34, 35]. Glomerular endothelial cells also respond Few human studies have examined the role of Ama-
dori-glycated proteins in the progression of diabetic re-to glycated albumin with increased PKC activity. As
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ciency in diabetic mice. The mechanisms by which gly-
cated serum proteins induce pathobiologic events in the
renal glomerulus are incompletely defined but may relate
to receptor-induced events followed by PKC-mediated
TGF-b activation (Fig. 1). Given that increased glycated
albumin levels potently stimulate renal extracellular ma-
trix production, therapeutic strategies that negate the
effects of glycated albumin are a logical approach to the
treatment of diabetic nephropathy.
Fig. 1. Dual pronged mechanism linking high ambient glucose concen-
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